Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 05, 2015 5:16 PM ET


Company Overview of Hetero Drugs Limited

Company Overview

Hetero Drugs Limited, a pharmaceutical company, develops, manufactures, and markets active pharmaceutical ingredients (APIs), intermediate chemicals, and generic finished dosages in India. The company offers APIs in the areas of antiretroviral and oncology products to the global pharmaceutical market; finished dosages in various therapeutic areas, including antiretroviral, gastro-intestinal, cardiovascular, antidepressants/antipsychotics, anti-diabetics, pain management, anti-infectives, dermatology, and oncology; and oncology products, including injectables, solid/liquid oral dosages, ointments, soft gelatine capsules, and inhalers. It also develops and manufactures bio-generics; and provid...




Hyderabad,  500018


Founded in 1993


91 40 2370 4923


91 40 2370 4926

Key Executives for Hetero Drugs Limited

Founder, Chairman and Managing Director
Age: 61
Whole Time Director
Age: 58
Director of Production and Whole Time Director
Age: 46
Compensation as of Fiscal Year 2015.

Hetero Drugs Limited Key Developments

Dr Reddy's Laboratories Enters into an Agreement with Hetero to Market Hepatitis C Drug Sofosbufir 400 mg Tablets

Dr Reddy's Laboratories announced it has entered into an agreement with Hetero to allow the company to distribute and market chronic Hepatitis C drug Sofosbufir 400 mg tablets, manufactured by Hetero, under the brand name Resof in India. Clinical studies have indicated that Sofosbuvir 400 mg in combination with other agents achieved high cure rates while shortening treatment duration to 12 weeks and reducing or completely eliminating the need for Interferon injections, depending on the viral genotype. According to the World health Organization, close to 12 million Indians suffer from chronic Hepatitis C, a disease that can seriously affect the liver, leading to potentially lifethreatening complications, including liver cancer. Earlier this month, two citybased pharma players, Natco Pharma Limited and Hetero, got approval to manufacture and market generic Sofosbuvir tablets 400 mg, from the Drugs Controller General of India. Sofosbuvir is sold globally by Gilead Sciences Inc. under the Sovaldi brand name. Both the Indian companies had announced that they will market generic Sofosbuvir at a price of INR 19,900 for a bottle of 28 tablets.

Hetero Drugs Limited Launches Darbepoetin Alfa in India

Hetero Drugs Limited announced the launch of its first biosimilar product in India, darbepoetin alfa. This launch marks a significant advancement for company in a biosimilars market expected to grow to USD 24 billion in the next five years. In partnership with several prominent pharmaceutical companies, Hetero is launching the drug across India. Darbepoetin alfa is a synthetic form of erythropoietin, clinically proven to stimulate erythropoiesis (increased hemoglobin levels) for patients with anemia due to chronic kidney disease.

Hetero Drugs Limited Presents at BioPharma India 2013, Nov-25-2013 04:00 PM

Hetero Drugs Limited Presents at BioPharma India 2013, Nov-25-2013 04:00 PM. Venue: Hyatt Regency, Mumbai, Maharashtra, India. Speakers: Shubhadeep Sinha, Head (Global) & Associate Vice-President, Clinical Development & Medical Affairs (CD&MA).

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hetero Drugs Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at